Daridorexant hydrochloride

近日，《中国成人失眠诊断与治疗指南（2023版）》发表于《中华神经科杂志》2024年6月刊，先声药业与瑞士Idorsia公司合作的新型抗失眠药盐酸达利雷生片获指南A级证据，I级推荐。失眠是最常见的睡眠问题之一。为规范国内失眠的诊断和治疗，中华医学会神经病学分会睡眠障碍学组在2012年推出《中国成人失眠诊断与治疗指南》，并于2017年修订。2023年新版结合了前版指南使用经验和当前具体国情，参考了国内外相关研究进展、新药和新型诊疗方法的应用，内容更丰富，科学性和实用性更强，更具临床指导价值。新版指南推荐DORA（双重食欲素拮抗剂）类药物为失眠治疗的首选新靶点用药。指南指出，达利雷生等DORA类药物能显著改善患者的主观入睡时间、总睡眠时间，改善睡眠结构和睡眠质量等。目前尚无证据表明DORA导致药物依赖，可以长期应用，停药不出现显著的反跳性失眠。新版指南明确推荐达利雷生“可改善夜间睡眠和日间功能，日间思睡发生比例低”，为该创新药独有优势。本次指南推荐证明达利雷生获得国内临床认可，有望为中国广大失眠患者提供新的选择。今年5月底，达利雷生中国III期临床研究已达到主要研究终点，进一步验证有效性及安全性。先声药业计划于年内向中国国家药品监督管理局提交盐酸达利雷生片上市申请。关于达利雷生达利雷生（海外商品名QUVIVIQTM）是一款治疗失眠的潜在Best-in-Class创新药。与传统镇静催眠药物通过镇静大脑来促进睡眠的疗法不同，达利雷生通过阻断食欲素神经肽（食欲素A和食欲素B）与其受体的结合，帮助患者入睡和保持睡眠，且次日无宿醉感、昏睡感。它是目前唯一获得欧洲药品管理局（EMA）批准的改善日间功能的DORA类失眠药物。目前，达利雷生已在美国、英国、欧盟、瑞士、加拿大获批上市。2022年11月15日，先声药业与Idorsia订立独家授权协议，获授达利雷生在大中华地区的开发及商业化独家权利。2024年5月20日，达利雷生获香港药剂业及毒药管理局签发的药品/制品注册证明书，准许“QUVIVIQ TABLETS 50MG”及“QUVIVIQ TABLETS 25MG”在中国香港销售、要约出售、分发及管有。

All Board proposals approved by the shareholders Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with very large majorities. The meeting was attended by 201 shareholders, representing a total of 90,297,668 shares, or 47.78% of the total outstanding shares. Led by the Chairman of the Board, Mathieu Simon, and Jean-Paul Clozel, who was the Chief Executive Officer for the year under review, the company presented the progress being made by the team at Idorsia. Mathieu Simon, MD, new Vice-Chairman and Lead Independent Director of Idorsia, commented:“In the last seven years Idorsia has made huge progress on all fronts. We have brought three drugs to the market, built a global marketing organization, and launched QUVIVIQ in the US and main European countries. In addition, we created a late-stage pipeline, continued to discover new drugs, re-acquired aprocitentan from Johnson & Johnson, and secured financing for all these achievements. It is reassuring to see that our shareholders appreciate what has been achieved and believe in the future of Idorsia by giving the new management team and the Board their endorsement through their votes. I would like to welcome Bart Filius to the board and congratulate Jean-Paul for election as Chairman. I’m confident that with the new composition, we are well prepared for the next chapter of Idorsia’s story.” Jean-Paul Clozel, MD, new Chairman of the Board of Directors, commented:“I would like to thank our shareholders for the trust they place in the Board and in me as the new Chairman. Today, a new phase will begin for Idorsia. In the coming months, the priorities will be to finance Idorsia, improve the commercial performance with QUVIVIQ, prepare for the launch of TRYVIO, and reinforce the pipeline. I am confident that Idorsia will soon return to a situation where the priority will be scientific and commercial excellence rather than financing. This will require the full commitment of the whole Idorsia team, and as a Board we are here to support them wherever needed.” The shareholders approved the Annual Report 2023, the Consolidated Financial Statements 2023, and the Statutory Financial Statements 2023. Shareholders also endorsed the Compensation Report 2023 and the Sustainability Report 2023 by way of consultative vote. The shareholders approved the appropriation of available earnings and that the net profit for the year 2023 be carried forward. The shareholders granted discharge to all members of the Board of Directors and of the Executive Committee for the financial year 2023. The shareholders approved the amendments to the company Articles of Association regarding share capital. The shareholders re-elected all Board members who stood for re-election and elected Bart Filius as a new Board member for a term of office until the conclusion of the AGM 2025. In addition, the shareholders elected Jean-Paul Clozel as Chairman of the Board, and the members of the Nominating, Governance and Compensation Committee: Srishti Gupta (Committee Chair), Sophie Kornowski, and Mathieu Simon. Following the AGM, the Board of Directors of Idorsia comprises a total of 6 members: Jean-Paul Clozel (Chairman), Mathieu Simon (Vice-Chairman and Lead Independent Director), Srishti Gupta, Sophie Kornowski, Sandy Mahatme, and Bart Filius. Shareholders approved the aggregate maximum amount of compensation for the Board of Directors (Non-Executive Directors) for the term of office until the AGM 2025 and aggregate maximum amount of compensation for the Idorsia Executive Committee (IEC) for the financial year 2025. BachmannPartner AG, who was represented by Mr Alain Bachmann, was re-elected as Independent Proxy for a term of office until the conclusion of the AGM 2025. Deloitte AG, Basel, was elected as the company's statutory auditors for the financial year 2024 (for a term of office until the conclusion of the AGM 2025). Notes to the editor About IdorsiaIdorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients. Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets. For further information, please contactAndrew C. WeissSenior Vice President, Head of Investor Relations & Corporate CommunicationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.commedia.relations@idorsia.com www.idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF